Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21654541 | 0.92 | PTK2 (0.48) | PTK2MAPTTHRBPOLBLMNA | |
| SCHEMBL21654795 | 0.90 | PTK2 (0.47) | PTK2MAPTTHRBPOLBLMNA | |
| SCHEMBL21654702 | 0.89 | PTK2 (0.41) | PTK2MAPTTHRBPOLBLMNA | |
| SCHEMBL21654528 | 0.89 | EGFR (0.42) | PTK2MAPTTHRBPOLBLMNA | |
| SCHEMBL21654642 | 0.88 | PTK2 (0.45) | PTK2MAPTTHRBPOLBLMNA | |
| SCHEMBL21654828 | 0.86 | PTK2 (0.39) | PTK2MAPTTHRBPOLBLMNA | |
| SCHEMBL21654811 | 0.86 | KMT2A (0.42) | PTK2MAPTTHRBPOLBPTGER1 | |
| SCHEMBL20030400 | 0.85 | PTK2 (0.39) | PTK2MAPTTHRBPOLBLMNA | |
| SCHEMBL21654798 | 0.85 | PTK2 (0.48) | PTK2MAPTTHRBPOLBTP53 | |
| SCHEMBL21654801 | 0.85 | NPC1 (0.39) | PTK2MAPTTHRBPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | INSTITUT PASTEUR KOREA (KR) | 2021-10-19 | — | — | US | disclosed |
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ST PHARM CO., LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031816-A1 | NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ZC3HAV1, ZC3HAV1L, HAVCR2 | PTK2 4377/4885MAPT 3619/4885THRB 3206/4885 |
| US-11149033-B2 | Heteroaryl compound, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and antiviral composition containing same as active ingredient | ZC3HAV1, ZC3HAV1L, HAVCR2 | PTK2 4380/4885MAPT 3439/4885THRB 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.